DexCom (NASDAQ:DXCM) Hits New 52-Week High – Time to Buy?

Posted by Francis Steltz on Aug 23rd, 2026

Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) reached a new 52-week high during trading on Friday . The company traded as high as $92.30 and last traded at $92.30, with a volume of 1834514 shares traded. The stock had previously closed at $90.22.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Robert W. Baird set a $105.00 price objective on shares of DexCom in a research note on Friday, July 31st. Benchmark upped their target price on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Sanford C. Bernstein set a $77.00 price target on DexCom in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft began coverage on DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Finally, Wells Fargo & Company boosted their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $88.71.

Get Our Latest Stock Report on DXCM

DexCom Stock Performance

The firm’s 50-day moving average price is $77.49 and its two-hundred day moving average price is $70.94. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $34.85 billion, a PE ratio of 36.50, a P/E/G ratio of 1.56 and a beta of 1.41.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the business posted $0.48 EPS. The company’s revenue was up 13.1% on a year-over-year basis. As a group, research analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,035 shares of company stock worth $5,446,673. 0.28% of the stock is currently owned by corporate insiders.

Institutional Trading of DexCom

A number of hedge funds have recently made changes to their positions in the stock. Saudi Central Bank grew its position in DexCom by 87.1% during the second quarter. Saudi Central Bank now owns 26,941 shares of the medical device company’s stock valued at $1,814,000 after purchasing an additional 12,545 shares in the last quarter. Plan A Wealth LLC purchased a new stake in DexCom in the 2nd quarter worth approximately $231,000. denkapparat Operations GmbH acquired a new stake in shares of DexCom during the 2nd quarter valued at $476,000. TD Waterhouse Canada Inc. boosted its stake in shares of DexCom by 40.4% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 6,704 shares of the medical device company’s stock valued at $462,000 after buying an additional 1,929 shares during the period. Finally, NEOS Investment Management LLC grew its holdings in shares of DexCom by 19.3% during the 2nd quarter. NEOS Investment Management LLC now owns 321,866 shares of the medical device company’s stock valued at $21,678,000 after acquiring an additional 52,085 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.